Peroxide-cleavable linkers for antibody-drug conjugates.


Journal

Chemical communications (Cambridge, England)
ISSN: 1364-548X
Titre abrégé: Chem Commun (Camb)
Pays: England
ID NLM: 9610838

Informations de publication

Date de publication:
09 Feb 2023
Historique:
pubmed: 2 2 2023
medline: 11 2 2023
entrez: 1 2 2023
Statut: epublish

Résumé

Antibody-drug conjugates containing peroxide-cleavable arylboronic acid linkers are described, which target the high levels of reactive oxygen species (ROS) in cancer. The arylboronic acid linkers rapidly release a payload in the presence of hydrogen peroxide, but remain stable in plasma. Anti-HER2 and PD-L1 peroxide-cleavable ADCs exhibited potent cytotoxicity

Identifiants

pubmed: 36722863
doi: 10.1039/d2cc06677g
pmc: PMC9910056
doi:

Substances chimiques

Immunoconjugates 0
Peroxides 0
Antineoplastic Agents 0
Hydrogen Peroxide BBX060AN9V
Acids 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1841-1844

Références

Chem Soc Rev. 2019 Aug 12;48(16):4361-4374
pubmed: 31294429
Tetrahedron Lett. 2018 Oct 3;59(40):3594-3599
pubmed: 31156276
Mol Cancer Ther. 2016 May;15(5):958-70
pubmed: 26944918
Biochim Biophys Acta Mol Cell Res. 2019 Dec;1866(12):118526
pubmed: 31398408
Chem Sci. 2018 Nov 9;10(3):694-700
pubmed: 30774870
Chem Commun (Camb). 2022 Feb 8;58(12):1962-1965
pubmed: 35044383
Angew Chem Int Ed Engl. 2017 Mar 1;56(10):2619-2622
pubmed: 28120377
Nat Rev Drug Discov. 2017 May;16(5):315-337
pubmed: 28303026
Eur J Med Chem. 2017 Dec 15;142:393-415
pubmed: 28911823
Chem Soc Rev. 2022 Nov 14;51(22):9182-9202
pubmed: 36322071
Cancer Res. 2008 Nov 15;68(22):9280-90
pubmed: 19010901
J Med Chem. 2018 Apr 26;61(8):3503-3515
pubmed: 29605999
Cancers (Basel). 2020 Mar 21;12(3):
pubmed: 32245171
Medchemcomm. 2019 May 8;10(9):1531-1549
pubmed: 31673314
ChemMedChem. 2019 Aug 6;14(15):1384-1391
pubmed: 31207139
Nat Biotechnol. 2003 Jul;21(7):778-84
pubmed: 12778055
Bioorg Chem. 2019 Oct;91:103158
pubmed: 31376782
Cancers (Basel). 2019 Feb 16;11(2):
pubmed: 30781490
J Med Chem. 2012 Jan 26;55(2):924-34
pubmed: 22185340

Auteurs

Nicola Ashman (N)

Yusuf Hamied Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge, CB2 1EW, UK. spring@ch.cam.ac.uk.

Jonathan D Bargh (JD)

Yusuf Hamied Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge, CB2 1EW, UK. spring@ch.cam.ac.uk.

Stephen J Walsh (SJ)

Yusuf Hamied Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge, CB2 1EW, UK. spring@ch.cam.ac.uk.
Cancer Research UK Cambridge Institute, Robinson Way, Cambridge, CB2 ORE, UK.

Ryan D Greenwood (RD)

Oncology R&D, AstraZeneca, Cambridge, CB4 OWG, UK.

Arnaud Tiberghien (A)

Spirogen, Astrazeneca, The QMB Innovation Centre, 42 New Rd, London, E1 2AX, UK.

Jason S Carroll (JS)

Cancer Research UK Cambridge Institute, Robinson Way, Cambridge, CB2 ORE, UK.

David R Spring (DR)

Yusuf Hamied Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge, CB2 1EW, UK. spring@ch.cam.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs
Humans Male Female Health Knowledge, Attitudes, Practice Middle Aged
Humans Female Alopecia Breast Neoplasms Middle Aged
1.00
Immunoconjugates Humans Antibodies, Bispecific Receptor, ErbB-2 Cell Line, Tumor

Classifications MeSH